COMMON VARIABLE IMMUNODEFICIENCY
Clinical trials for COMMON VARIABLE IMMUNODEFICIENCY explained in plain language.
Never miss a new study
Get alerted when new COMMON VARIABLE IMMUNODEFICIENCY trials appear
Sign up with your email to follow new studies for COMMON VARIABLE IMMUNODEFICIENCY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Radical transplant offers hope for a 'Factory Reset' of the immune system
⭐️ CURE ⭐️ OngoingThis study is testing whether a bone marrow or blood stem cell transplant from a healthy donor can cure people with serious disorders where their own T-cells (a type of immune cell) are overactive or malfunctioning. These disorders can cause life-threatening infections, organ dam…
Matched conditions: COMMON VARIABLE IMMUNODEFICIENCY
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: ⭐️ CURE ⭐️
Last updated Mar 30, 2026 14:32 UTC
-
New hope: rebuilding broken immune systems with donor cells
Disease control OngoingThis study is testing a treatment to rebuild the immune system in people with severe inherited immune deficiencies. Patients receive stem cells from a donor, which are meant to grow into healthy new immune cells. The goal is to control the disease and reduce life-threatening infe…
Matched conditions: COMMON VARIABLE IMMUNODEFICIENCY
Phase: NA • Sponsor: Masonic Cancer Center, University of Minnesota • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
Natural supplement trial offers hope for rare immune disorder lung damage
Disease control ENROLLING_BY_INVITATIONThis study is testing whether a supplement called Fisetin can help treat lung scarring in people with common variable immunodeficiency (CVID), a rare immune system disorder. Twenty participants will receive either Fisetin or a placebo to see if it improves lung function, reduces …
Matched conditions: COMMON VARIABLE IMMUNODEFICIENCY
Phase: PHASE2 • Sponsor: Avni Joshi • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC